KRAS <sup>G12C</sup> Inhibition with Sotorasib in Advanced Solid Tumors

20201,647 citationsJournal Articlegreen Open Access

Authors

David S. Hong · The University of Texas MD Anderson Cancer Center

Marwan Fakih · City of Hope

John H. Strickler · City of Hope

Jayesh Desai · The Royal Melbourne Hospital

Gregory A. Durm · City of Hope

Geoffrey I. Shapiro · Harvard University

Gerald S. Falchook ·

Abstract

Sotorasib showed encouraging anticancer activity in patients with heavily pretreated advanced solid tumors harboring the <i>KRAS</i> p.G12C mutation. Grade 3 or 4 treatment-related toxic effects occurred in 11.6% of the patients. (Funded by Amgen and others; CodeBreaK100 ClinicalTrials.gov number, NCT03600883.).

Topics & Keywords

Cancer, Hypoxia, and Metabolism Enzyme Structure and Function Biochemical and Molecular Research

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 383, Issue 13, pp. 1207-1217

DOI: 10.1056/nejmoa1917239

Field-Weighted Citation Impact: 84.50